{"nctId":"NCT01575834","briefTitle":"Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis","startDateStruct":{"date":"2012-03-15","type":"ACTUAL"},"conditions":["Postmenopausal Osteoporosis"],"count":7180,"armGroups":[{"label":"Romosozumab","type":"EXPERIMENTAL","interventionNames":["Drug: Romosozumab","Drug: Denosumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Denosumab"]}],"interventions":[{"name":"Romosozumab","otherNames":["AMG 785","EVENITY™"]},{"name":"Placebo","otherNames":[]},{"name":"Denosumab","otherNames":["Prolia®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Postmenopausal women with osteoporosis, defined as low bone mineral density (BMD T-score at the total hip or femoral neck of ≤ -2.50)\n\nExclusion Criteria:\n\n* BMD T-score of ≤ -3.50 at the total hip or femoral neck\n* History of hip fracture\n* Any severe or more than 2 moderate vertebral fractures, as assessed by the central imaging based on lateral spine x-rays\n* Use of agents affecting bone metabolism\n* History of metabolic or bone disease (except osteoporosis)\n* Vitamin D insufficiency (vitamin D repletion and rescreening is permitted)\n* Current hyper- or hypocalcemia\n* Current, uncontrolled hyper- or hypothyroidism\n* Current, uncontrolled hyper- or hypoparathyroidism","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"55 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With New Vertebral Fracture Through Month 12","description":"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.\n\nThe Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:\n\n* Grade 0 (Normal) = no fracture;\n* Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);\n* Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;\n* Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With New Vertebral Fracture Through Month 24","description":"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.\n\nThe Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:\n\n* Grade 0 (Normal) = no fracture;\n* Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);\n* Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;\n* Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Clinical Fracture Through Month 12","description":"Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Nonvertebral Fracture Through Month 12","description":"A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Nonvertebral Fracture Through Month 24","description":"A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date as recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Clinical Fracture Through Month 24","description":"Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Major Nonvertebral Fracture Through Month 12","description":"A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Major Nonvertebral Fracture Through Month 24","description":"A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 12","description":"A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24","description":"A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Hip Fracture Through Month 12","description":"Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Hip Fracture Through Month 24","description":"Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Major Osteoporotic Fracture Through Month 12","description":"Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Major Osteoporotic Fracture Through Month 24","description":"Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12","description":"A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24","description":"A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.1"},{"groupId":"OG001","value":"13.1","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 24","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"0.1"},{"groupId":"OG001","value":"16.6","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 12","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.1"},{"groupId":"OG001","value":"6.0","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"0.1"},{"groupId":"OG001","value":"8.5","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 12","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.1"},{"groupId":"OG001","value":"5.5","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 24","description":"Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"0.1"},{"groupId":"OG001","value":"7.3","spread":"0.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":314,"n":3576},"commonTop":["Arthralgia","Nasopharyngitis","Back pain","Fall","Pain in extremity"]}}}